Comparison of fetal mesencephalic grafts, AAV-delivered GDNF, and both combined in an MPTP-induced nonhuman primate Parkinson's model.

[1]  R. Roth,et al.  Impact of methamphetamine on dopamine neurons in primates is dependent on age: implications for development of Parkinson's disease , 2011, Neuroscience.

[2]  Kenneth P Vives,et al.  Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  E. Huang,et al.  Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. , 2009, Human gene therapy.

[4]  R. Roth,et al.  Embryonic substantia nigra grafts in the mesencephalon send neurites to the host striatum in non‐human primate after overexpression of GDNF , 2009, The Journal of comparative neurology.

[5]  P. Pivirotto,et al.  Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. , 2009, Human gene therapy.

[6]  P. Pivirotto,et al.  Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. , 2009, Human gene therapy.

[7]  D. Howells,et al.  Stimulation of axonal sprouting by trophic factors immobilized within the wound core , 2008, Brain Research.

[8]  R. Roth,et al.  AAV2-mediated gene transfer of GDNF to the striatum of MPTP monkeys enhances the survival and outgrowth of co-implanted fetal dopamine neurons , 2008, Experimental Neurology.

[9]  Elisabet Englund,et al.  Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.

[10]  R. Roth,et al.  Embryonic Substantia Nigra Grafts Show Directional Outgrowth to Cografted Striatal Grafts and Potential for Pathway Reconstruction in Nonhuman Primate , 2008, Cell transplantation.

[11]  R. Roth,et al.  Development of A9/A10 dopamine neurons during the second and third trimesters in the African green monkey , 2005, The Journal of comparative neurology.

[12]  A. Dagher,et al.  Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. , 2005, Brain : a journal of neurology.

[13]  A. Björklund,et al.  Overexpression of Glial Cell Line-Derived Neurotrophic Factor Using a Lentiviral Vector Induces Time- and Dose-Dependent Downregulation of Tyrosine Hydroxylase in the Intact Nigrostriatal Dopamine System , 2004, The Journal of Neuroscience.

[14]  R. Ridley,et al.  Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson’s disease in marmoset monkeys , 2003, Experimental Neurology.

[15]  Yi Ai,et al.  Intraputamenal infusion of GDNF in aged rhesus monkeys: Distribution and dopaminergic effects , 2003, The Journal of comparative neurology.

[16]  D. Kirik,et al.  Long‐term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system , 2003, The European journal of neuroscience.

[17]  Stanley Fahn,et al.  Dyskinesia after fetal cell transplantation for parkinsonism: A PET study , 2002, Annals of neurology.

[18]  A. Björklund,et al.  Aberrant Sprouting and Downregulation of Tyrosine Hydroxylase in Lesioned Nigrostriatal Dopamine Neurons Induced by Long-Lasting Overexpression of Glial Cell Line Derived Neurotrophic Factor in the Striatum by Lentiviral Gene Transfer , 2002, Experimental Neurology.

[19]  Redmond De.  Cellular replacement therapy for Parkinson's disease--where we are today? , 2002 .

[20]  A. Björklund,et al.  Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector , 2002, Neuroreport.

[21]  R. Samulski,et al.  Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad Specificity , 2002, Journal of Virology.

[22]  A. Björklund,et al.  Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6‐OHDA lesion model depends on the site of administration of the trophic factor , 2000, The European journal of neuroscience.

[23]  J. Bloch,et al.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.

[24]  A. Björklund,et al.  Long-Term rAAV-Mediated Gene Transfer of GDNF in the Rat Parkinson's Model: Intrastriatal But Not Intranigral Transduction Promotes Functional Regeneration in the Lesioned Nigrostriatal System , 2000, The Journal of Neuroscience.

[25]  J. Bloch,et al.  Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease. , 2000, Human gene therapy.

[26]  R. Roth,et al.  Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment , 1999, Neuroscience.

[27]  V. Choi,et al.  Production of Recombinant Adeno‐Associated Viral Vectors and Use in In Vitro and In Vivo Administration , 1999, Current protocols in neuroscience.

[28]  P. Aebischer,et al.  Encapsulated cells as therapy. , 1999, Scientific American.

[29]  R. Samulski,et al.  Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus , 1998, Journal of Virology.

[30]  C. Spenger,et al.  Implants of Polymer-Encapsulated Genetically Modified Cells Releasing Glial Cell Line-Derived Neurotrophic Factor Improve Survival, Growth, and Function of Fetal Dopaminergic Grafts , 1998, Experimental Neurology.

[31]  Blunt,et al.  Long‐term protection of the rat nigrostriatal dopaminergic system by glial cell line‐derived neurotrophic factor against 6‐hydroxydopamine in vivo , 1998, The European journal of neuroscience.

[32]  W. Cass,et al.  GDNF Protection against 6-OHDA: Time Dependence and Requirement for Protein Synthesis , 1997, The Journal of Neuroscience.

[33]  D. Russell,et al.  Intranigral or intrastriatal injections of GDNF: effects on monoamine levels and behavior in rats. , 1996, European journal of pharmacology.

[34]  John L. Hudson,et al.  Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo , 1995, Brain Research Bulletin.

[35]  A. Björklund,et al.  Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Rosenstein.  Why Do Neural Transplants Survive? An Examination of Some Metabolic and Pathophysiological Considerations in Neural Transplantation , 1995, Experimental Neurology.

[37]  P R Sanberg,et al.  Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. , 1995, The New England journal of medicine.

[38]  L. Olson,et al.  Glial Cell Line-Derived Neurotrophic Factor Is Expressed in the Developing but Not Adult Striatum and Stimulates Developing Dopamine Neurons in Vivo , 1993, Experimental Neurology.

[39]  J. Lile,et al.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.

[40]  M. Lawrence,et al.  MPTP lesions and dopaminergic drugs alter eye blink rate in African green monkeys , 1991, Pharmacology Biochemistry and Behavior.

[41]  A. Grace,et al.  Compensations after lesions of central dopaminergic neurons: some clinical and basic implications , 1990, Trends in Neurosciences.

[42]  S. Hsu,et al.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[43]  D. Redmond.  Behavioral Assessment in the African Green Monkey After MPTP Administration , 2011 .

[44]  R. Roth,et al.  Grafting of fetal substantia nigra to striatum reverses behavioral deficits induced by MPTP in primates: a comparison with other types of grafts as controls , 2004, Experimental Brain Research.

[45]  A. Bonnet,et al.  [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.

[46]  Andrew Freese,et al.  In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector , 1998, Gene Therapy.

[47]  M. Woodruff,et al.  Toxin-Induced Models of Neurological Disorders , 1994, Springer US.

[48]  R. Roth,et al.  Behavioral Effects of MPTP Administration in the Vervet Monkey , 1994 .

[49]  S. Fahn.  Unified Parkinson's Disease Rating Scale , 1987 .

[50]  S. Fahn.  Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[51]  C. Marsden,et al.  Recent Developments in Parkinson's Disease , 1986 .